Contraceptive vaccine hCG - Aphton

Drug Profile

Contraceptive vaccine hCG - Aphton

Alternative Names: Anti-hCG immunocontraceptive - Aphton; Anti-hCG vaccine - Aphton; hCG vaccine - Aphton

Latest Information Update: 22 Mar 2007

Price : $50

At a glance

  • Originator Aphton Corporation
  • Developer Aphton Corporation; World Health Organization
  • Class Contraceptives; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Contraception

Most Recent Events

  • 01 Sep 2006 Discontinued - Phase-II for Contraception/Pregnancy (Prevention) in Europe (Parenteral)
  • 08 Oct 2003 The phase II trial of the contraceptive vaccine is on hold pending further funding from the WHO
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top